Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

The following is a summary of “Treatment of Hypothalamic Obesity With GLP-1 Analogs,” published in the November 2024 issue of Endocrinology by Dimitri and Roth. Damage to hypothalamic nuclei or ...

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

Semaglutide is helping patients achieve weight loss previously achievable only with bariatric surgery. But at what cost?

GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome ... result in significant decrease in efficacy of the medication class. LA GLP1-RAs in studies to date appear ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the ... while newer GLP-1-targeting drugs like Ozempic and Wegovy, as well as Eli Lilly’s ...

A study has found a higher risk of suicidal thoughts in users of Novo Nordisk's GLP-1 agonist-based drugs for diabetes and obesity, even though regulators in the US and EU concluded there was no ...

a GLP-1 agonist marketed by Novo Nordisk under the brand names Ozempic and Wegovy when administered together but now to potentially sustain these effects after a GLP-1’s discontinuation. “One of the ...